title: Autologous adrenal medullary, fetal mesencephalic, and fetal adrenal brain transplantation in Parkinson's disease: a long-term postoperative follow-up.
abstract: We report on the clinical status of 5 patients with Parkinson's disease (PD) 3 years after autologous adrenal medullary (AM)-to-caudate nucleus (CN) implantation, and of 2 PD patients, 2 years after fetal ventral mesencephalon (VM)- and fetal adrenal (A)-to-CN homotransplantation. Current clinical evaluation of 4 of the AM grafted patients revealed sustained bilateral amelioration of their PD signs, most notably of rigidity, postural imbalance and gait disturbances, resulting in a substantial improvement in their quality of life. The disease-related dystonia of one of them disappeared only 2 years after surgery. The levodopa requirements of 2 of these patients and the anticholinergic therapy of another have been reduced. In agreement with the satisfactory clinical evaluation of these 4 patients, their neuropsychological and electrophysiological improvements, initially registered 3 months after surgery, have been maintained for 3 years. After 1 year of significant recovery, the 5th patient of this group has almost returned to her preoperative state. The 2 homotransplanted patients also showed sustained bilateral improvement of their PD signs. Two years after surgery, the most improved signs of the fetal VM case were rigidity, bradykinesia, postural imbalance, gait disturbances and facial expression. The fetal A case has only shown amelioration of rigidity and bradykinesia. Neither of them has shown significant neuropsychological changes. Their current levodopa requirements are less than before surgery. The improvements shown here by PD patients after brain tissue grafts go beyond those obtained using any other therapeutic approach, when levodopa fails. Although more studies and the development of these procedures are obviously required, these initial human trials appear to be resisting the test of time.
authors.affiliation: Department of Clinical Research in Neurology and Neurosurgery, Hospital de Especialidades, Mexico City, Mexico.
authors.forename: I
authors.initials: I
authors.lastname: Madrazo
authors.forename: R
authors.initials: R
authors.lastname: Franco-Bourland
authors.forename: M
authors.initials: M
authors.lastname: Aguilera
authors.forename: F
authors.initials: F
authors.lastname: Ostrosky-Solis
authors.forename: M
authors.initials: M
authors.lastname: Madrazo
authors.forename: C
authors.initials: C
authors.lastname: Cuevas
authors.forename: H
authors.initials: H
authors.lastname: Catrejon
authors.forename: G
authors.initials: G
authors.lastname: Guizar-Zahagun
authors.forename: E
authors.initials: E
authors.lastname: Magallon
mesh_terms: D000311:Adrenal Glands / Q000196:embryology / Q000637:transplantation*; D000313:Adrenal Medulla / Q000637:transplantation*; D000328:Adult; D016380:Brain Tissue Transplantation; D002421:Caudate Nucleus; D003131:Combined Modality Therapy; D005069:Evaluation Studies as Topic; D005260:Female; D016332:Fetal Tissue Transplantation; D005500:Follow-Up Studies; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008636:Mesencephalon / Q000196:embryology / Q000637:transplantation*; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy / Q000601:surgery*; D011788:Quality of Life; D012720:Severity of Illness Index; D014182:Transplantation, Autologous
chemical_list: D007980:Levodopa